首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   67012篇
  免费   5187篇
  国内免费   2318篇
  74517篇
  2024年   90篇
  2023年   373篇
  2022年   971篇
  2021年   1554篇
  2020年   1125篇
  2019年   1338篇
  2018年   1661篇
  2017年   1421篇
  2016年   2148篇
  2015年   3406篇
  2014年   3928篇
  2013年   4412篇
  2012年   5710篇
  2011年   5337篇
  2010年   3499篇
  2009年   3224篇
  2008年   4299篇
  2007年   4049篇
  2006年   3617篇
  2005年   3359篇
  2004年   3079篇
  2003年   2709篇
  2002年   2337篇
  2001年   1784篇
  2000年   1643篇
  1999年   1378篇
  1998年   646篇
  1997年   537篇
  1996年   428篇
  1995年   375篇
  1994年   353篇
  1993年   280篇
  1992年   461篇
  1991年   402篇
  1990年   356篇
  1989年   312篇
  1988年   230篇
  1987年   232篇
  1986年   184篇
  1985年   133篇
  1984年   98篇
  1983年   119篇
  1982年   80篇
  1981年   71篇
  1980年   63篇
  1979年   86篇
  1978年   65篇
  1977年   63篇
  1976年   53篇
  1974年   70篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
Recent improvements to SrAl2O4:Eu2+, Dy3+ phosphors have enabled the use of luminescent hosts with a stable crystal structure and high physical and chemical stability, thus overcoming the bottleneck in the applicability of ZnS:Cu phosphors. However, enhancement of afterglow lifetime and brightness in SrAl2O4:Eu2+, Dy3+ phosphors remains a challenging task. Here, we have improved the afterglow characteristics in terms of persistence time and brightness by a systematic investigation of the composition of Eu-doped alkaline earth aluminate SrAl2O4:Eu2+, Dy3+ crystals. We found that a Dy3+/Eu2+ ratio of ~2.4 and ~0.935 mol Eu2+ (per mol of SrAl2O4) gave the brightest and longest emissions (11% and 9% increase for each). Doping with Si4+ also resulted in a slight increase in brightness up to ~15%. Doping with alkali metal or alkaline earth metal significantly enhanced the phosphorescence intensity. In particular, doping with 0.005 mol Li+ (per mol of SrAl2O4) alone boosted the phosphorescence intensity to 239% of the initial value, as compared to that observed for the non-doped crystal, while doping with 0.01 mol Mg2+ and 0.005 mol Li+ (per 1 mol SrAl2O4) boosted the phosphorescence intensity up to 313% of the initial value. The results of this investigation are expected to act as a guideline for the synthesis of bright and long persistent phosphors, and facilitate the development of persistent phosphors with afterglow characteristics superior to those of conventional phosphors.  相似文献   
32.
A recombinant DNA, encoding the chimeric protein of the signal sequence for bifidobacterial α-amylase mature pediocin PA-1, was introduced into Bifidobacterium longum MG1. Biologically active pediocin PA-1 was successfully secreted from the strain and showed bactericidal activity against Listeria monocytogenes and the same molecular mass as native pediocin PA-1.  相似文献   
33.
34.
35.
36.
37.
38.
39.
Changsung Kim 《BMB reports》2015,48(5):256-265
Cardiovascular and neurodegenerative diseases are major health threats in many developed countries. Recently, target tissues derived from human embryonic stem (hES) cells and induced pluripotent stem cells (iPSCs), such as cardiomyocytes (CMs) or neurons, have been actively mobilized for drug screening. Knowledge of drug toxicity and efficacy obtained using stem cell-derived tissues could parallel that obtained from human trials. Furthermore, iPSC disease models could be advantageous in the development of personalized medicine in various parts of disease sectors. To obtain the maximum benefit from iPSCs in disease modeling, researchers are now focusing on aging, maturation, and metabolism to recapitulate the pathological features seen in patients. Compared to pediatric disease modeling, adult-onset disease modeling with iPSCs requires proper maturation for full manifestation of pathological features. Herein, the success of iPSC technology, focusing on patient-specific drug treatment, maturation-based disease modeling, and alternative approaches to compensate for the current limitations of patient iPSC modeling, will be further discussed. [BMB Reports 2015; 48(5): 256-265]  相似文献   
40.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号